Arch Venture Management’s Unity Biotechnology UBX Stock Holding History

Arch Venture Management’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,004,817	Closed	-$386K	–	10
2025 Q2	$386K	Hold	1,004,817	–	–	0.13%	10
2025 Q1	$1.05M	Hold	1,004,817	–	–	0.51%	7
2024 Q4	$981K	Hold	1,004,817	–	–	0.43%	8
2024 Q3	$1.48M	Hold	1,004,817	–	–	0.57%	8
2024 Q2	$1.36M	Hold	1,004,817	–	–	0.51%	7
2024 Q1	$1.65M	Hold	1,004,817	–	–	2.05%	8
2023 Q4	$1.94M	Hold	1,004,817	–	–	1.19%	6
2023 Q3	$2.41M	Hold	1,004,817	–	–	1.57%	6
2023 Q2	$2.56M	Hold	1,004,817	–	–	1.58%	6
2023 Q1	$1.64M	Hold	1,004,817	–	–	0.79%	8
2022 Q4	$2.75M	Sell	1,004,817 -1	-0%	-$3	0.71%	7
2022 Q3	$3.97M	Buy	+1,004,818	New	+$6.34M	0.51%	8

Other funds holding UBX

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return

AWM

AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Arch Venture Management's UBX Position: Q3 2025 in Review

Arch Venture Management sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 1,004,817 shares — an estimated $386K sold.

Arch Venture Management first reported a position in UBX in Q3 2022 and held it in 12 quarters. The position peaked at $3.97M in Q3 2022. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

Arch Venture Management reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
Arch Venture Management sold 1,004,817 Unity Biotechnology shares in Q3 2025, an estimated $386K.
Arch Venture Management first reported a position in Unity Biotechnology in Q3 2022 and held it in 12 quarters.
Arch Venture Management's Unity Biotechnology position peaked at $3.97M in Q3 2022.
6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Arch Venture Management's 13F filing for Q3 2025, filed 14 Nov 2025.